Heterocyclic compounds can be divided into two categories: alicyclic heterocycles and aromatic heterocycles. Compounds whose heterocycles in the molecular skeleton cannot reflect aromaticity are called alicyclic heterocyclic compounds. Compound: 3685-23-2, is researched, Molecular C7H13NO2, about Effects of Atractylodes Oil on Inflammatory Response and Serum Metabolites in Adjuvant Arthritis Rats, the main research direction is atractylodes oil effect inflammatory response serum metabolites adjuvant arthritis; AIA; Atractylodes Rhizoma; Atractylodes oil; Metabolomics; Rheumatoid arthritis.Related Products of 3685-23-2.
Atractylodes Rhizoma is one of two principal components in Ermiaosan, a well-known traditional Chinese medicine for the treatment of rheumatoid arthritis (RA). Atractylodes oil (AO) represents a potential alternative treatment for RA. The purpose of this study was to investigate the effect of AO in rats with Adjuvant Arthritis (AA) by exploration of changes in serum metabolites using gas chromatog.-mass spectrometry (GC-MS). Foot thickness and arthritis score, ankle joint pathol. structure, the concentrations of TNF-α, IL-1β, IL-6, IL-17 and the expression of MMPs in ankle joint tissue were measured as indicators of efficacy of treatment using AO. In addition, multivariate statistical anal. was used to identify differential production of metabolites and biomarkers, and to analyze metabolic pathways. The results demonstrate that administration of AO resulted in a good therapeutic effect in the AA rat model, with significantly improved joint swelling, reduced joint score, and inhibition of inflammation, synovial pannus hyperplasia, and bone and cartilage destruction. Furthermore, AO was found to exert its effect against rheumatoid arthritis principally by differentially affecting 11 metabolites and six metabolic pathways, predominantly related to abnormal amino acid metabolism, in addition to energy-related metabolic pathways. This study evaluated the capability of AO to effectively treat AA rats, providing a novel strategy for the treatment of RA.
Here is a brief introduction to this compound(3685-23-2)Related Products of 3685-23-2, if you want to know about other compounds related to this compound(3685-23-2), you can read my other articles.
Reference:
Synthesis and Crystal Structure of a Chiral C3-Symmetric Oxygen Tripodal Ligand and Its Applications to Asymmetric Catalysis,
Chiral lanthanide(III) complexes of sulphur–nitrogen–oxygen ligand derived from aminothiourea and sodium D-camphor-β-sulfonate